Papers: 10.18632/oncotarget.21877

https://doi.org/10.18632/oncotarget.21877

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations

Cited by: 14
Author(s): Anne-Kathrin Garz, Saskia Wolf, Sonja Grath, Verena I. Gaidzik, Stefan Habringer, Binje Vick, Martina Rudelius, Christoph Ziegenhain, Sylvia Herold, Marie‐Theresa Weickert, Martha Smets, Christian Peschel, Robert A.J. Oostendorp, Sebastian Bultmann, Irmela Jeremias, Christian Thiede, Konstanze Döhner, Ulrich Keller, Katharina Götze
Published: about 9 years ago

Software Mentions 1